FDA approves new blood test for colorectal cancer screening, offering a simpler and less invasive option compared to colonoscopy. The test has an 83% sensitivity for detecting colorectal cancer.
Key Points
FDA approves Shield, a blood test for colorectal cancer screening
Test has 83% sensitivity for detecting colorectal cancer
Offered as a primary screening option for average-risk individuals aged 45 and older
Pros
Simpler and less invasive than colonoscopy
Can be done during a routine doctor's appointment
Designed for average-risk individuals aged 45 and older
Cons
Lower sensitivity compared to some stool tests
Not as effective in preventing colorectal cancer by detecting and removing precursor lesions